Skip to main content
OpenTrials

Clinical trial condition

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Explore clinical trials studying HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy trial results

Active, Not Recruiting

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

NCT06126640

Conditions
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Locations
  • Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
  • Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin Municipality, China
View Trial Details